

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Equality impact assessment

IPG565 Miniature lens system implantation for advanced age-related macular degeneration

The impact on equality has been assessed during guidance development according to the principles of the NICE Equality scheme.

Scoping

1. Have any potential equality issues been identified during the scoping process (development of the scope or discussion at the Committee meeting), and, if so, what are they?

In 2012, the estimated prevalence of late age-related macular degeneration (AMD) in the UK was 2.4% (equivalent to 513, 000 cases). The prevalence is estimated to increase to 679,000 by 2020.

The prevalence of AMD increases with increasing age. Approximately 1 in 100 people aged 65-75, and about 1 in 8 people aged over 85 have AMD severe enough to cause serious visual loss. It affects more women than men and is more common in people from Caucasian (white) racial backgrounds than from other racial groups.

Some patients with AMD will be covered by the equalities legislation Disability Discrimination Act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? (If there are exclusions listed in the scope (for example, populations, treatments or settings), are these justified?)

This was not thought to have an impact on the assessment of the procedure.

3. Has any change to the scope (such as additional issues raised during the Committee meeting) been agreed to highlight potential equality

issues?
No

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?
No specific data relating to potential equality issues were identified in the literature presented in the overview.

2. Have any other potential equality issues been raised in the overview, specialist adviser questionnaires or patient commentary, and, if so, how has the Committee addressed these?
No issues were raised in the overview and specialist adviser questionnaires. Patients commentaries received after consultation were discussed by the committee and changes made to the FIPD (see FIPD section below).

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?
No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5.	Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
Not applicable	

6.	Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligation to promote equality?
Not applicable	

7.	Have the Committee's considerations of equality issues been described in the consultation document, and, if so, where?
No	

Final interventional procedures document

1.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?
<p>Commentaries from patients who had experience of this procedure were received after consultation and were discussed by the committee. In response to these comments, the committee added a comment in 6.4 of the FIPD as follows:</p> <p>6.4 The committee noted that patient commentaries were mixed. Some patients reported good improvement in quality of vision whereas others reported difficulty in coping with high magnification images and did not achieve a satisfactory improvement in vision.</p>	

2.	If the recommendations have changed after consultation, are there
----	---

any recommendations that make it more difficult in practice for a specific group to access a technology or intervention compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

Not applicable

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

Not applicable

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

Not applicable

5. Have the Committee's considerations of equality issues been described in the final interventional procedures document, and, if so, where?

6. Yes, in section 6 of the FIPD (see 6.4).

Approved by Programme Director and Clinical Advisor

Date: 27/07/2016